Showing 3451-3460 of 5689 results for "".
- Miracles in Sight Seeks to Expand Adoption of Innovative Surgery With Prepared DMEK Graftshttps://modernod.com/news/miracles-in-sight-seeks-to-expand-adoption-of-innovative-surgery-with-prepared-dmek-grafts/2480128/Across the world, Descemet Membrane Endothelial Keratoplasty (DMEK) is becoming the standard of care for endothelial dysfunction. Miracles In Sight (MIS), a nonprofit eye bank that recovers, processes, and distributes ocular tissue, is helping reduce the learning curve for this new surgical techn
- Moorfields Eye Hospital Dubai in Collaboration with Moorfields Eye Hospital Abu Dhabi Develop Procedure to Diagnose Retinal Problems in Childrenhttps://modernod.com/news/moorfields-eye-hospital-dubai-in-collaboration-with-moorfields-eye-hospital-abu-dhabi-develop-procedure-to-diagnose-retinal-problems-in-children/2480152/A medical study on diagnosing children undertaken in the United Arab Emirates by a team of four consultants at Moorfields Eye Hospital Dubai and Moorfields Eye Hospital Abu Dhabi has achieved the distinction of becoming the first medical study undertaken entirely in the UA
- Retinal Changes on OCT Angiography May Flag Early Alzheimer’shttps://modernod.com/news/retinal-changes-on-oct-angiography-may-flag-early-alzheimers/2480158/Microvascular changes in the retina detected by using noninvasive optical coherence tomography (OCT) angiography align well with imaging and biomarker evidence of preclinical Alzheimer’s disease, a new study shows, according to a Medscape
- Bausch + Lomb Launches Lumify, the First OTC Redness Relieving Eye Drop With Low-Dose Brimonidinehttps://modernod.com/news/bausch-lomb-launches-lumify-the-first-otc-redness-relieving-eye-drop-with-low-dose-brimonidine/2480169/Bausch + Lomb announced the launch of Lumify (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. “With the availability of Lumify, consumers now have an in
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- ianTECH’s miLOOP Grabs Two “Best Paper of Session” Wins at the ASCRS-ASOA Annual Meetinghttps://modernod.com/news/iantechs-miloop-grabs-two-best-paper-of-session-wins-at-the-ascrs-asoa-annual-meeting/2480210/Two presentations among the several featuring ianTECH’s novel »miLOOP Device won “Best Paper in Session” awards during the 2018 meeting of the American Society of Catarac
- Omeros: Omidria Demonstrates Benefits Across Traditional and Femtosecond Laser-Assisted Cataract Surgery and in IFIS Caseshttps://modernod.com/news/omeros-omidria-demonstrates-benefits-across-traditional-and-femtosecond-laser-assisted-cataract-surgery-and-in-ifis-cases/2480226/Omeros announced that the results of four real-world clinical studies evaluating the benefits of Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Imprimis to Feature its Cyclosporine/Chondroitin Sulfate and Non-Opioid MKO Melt Formulations at the Upcoming ASCRS Meetinghttps://modernod.com/news/imprimis-to-feature-its-cyclosporine-chondroitin-sulfate-and-non-opioid-mko-melt-formulations-at-the-upcoming-ascrs-meeting/2480266/Imprimis Pharmaceuticals and its ophthalmology-focused ImprimisRx division announced its participation and related physician presentations at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington,
- Dallas Lighthouse for the Blind to Merge With Envisionhttps://modernod.com/news/dallas-lighthouse-for-the-blind-to-merge-with-envision/2480267/Envision announced that it has acquired the Dallas Lighthouse for the Blind. Operations will continue as normal in Dallas, and the Dallas Lighthouse for the Blind name will be retained. Financial terms of the deal were not disclosed. The merger will have positive benefits both in Te